You are here
ORIC Pharmaceuticals Appoints Edna Chow Maneval, PhD, as Senior Vice President of Clinical Development
SOUTH SAN FRANCISCO, Calif., March 4, 2019 /PRNewswire/ -- ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on the discovery and development of novel therapies against treatment-resistant cancers, announced that Edna Chow Maneval, PhD, has been named Senior Vice President of Clinical Development. Dr. Chow Maneval will serve on the executive leadership team and, together with Chief Medical Officer Pratik Multani, MD, lead clinical development for ORIC.
"ORIC continues to attract top talent to its leadership team with our newest addition, Edna Chow Maneval. Edna has a multi-decade track record of leadership and success in oncology drug development, including multiple new drug applications during her time at Ignyta, Aragon, and Pfizer," said Jacob Chacko, MD, Chief Executive Officer of ORIC. "We are pleased that she is joining ORIC at this critical inflection point as we begin clinical studies of ORIC-101 in patients with solid tumors and continue to progress our pipeline."
"I am excited to join ORIC and work with its accomplished founders and scientists," said Dr. Chow Maneval. "ORIC is at the forefront of work to address the challenge of treatment resistance in advanced cancers, beginning with Phase 1b studies of the glucocorticoid receptor antagonist in multiple patient populations and continuing with the rest of the pipeline."
Dr. Chow Maneval brings to ORIC more than 20 years of clinical development experience in oncology. Most recently, she was Senior Vice President of Clinical Development at Ignyta (acquired by Roche in 2018), where she was the clinical lead for entrectinib, a molecularly-targeted therapy for rare cancers affecting adult and pediatric patients. Prior to Ignyta, she was Vice President of Clinical Development of Aragon (acquired by Johnson & Johnson in 2013) and Seragon (acquired by Genentech in 2014), responsible for the apalutamide (ERLEADA™) and SERD clinical programs in prostate and breast cancers, respectively. Dr. Chow Maneval's career in drug development started at Pfizer, where she held positions of increasing responsibility within the oncology group, primarily dedicated to the development and approval of sunitinib (SUTENT™). In 2013, Dr. Chow Maneval was a YWCA TWIN (Tribute to Women & Industry) honoree. She holds a PhD in Biomedical Engineering from the University of Southern California.
About ORIC Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor. ORIC's pipeline also includes an orally-available small molecule inhibitor of CD73, as well as other undisclosed programs targeting mechanisms of oncology therapy resistance. ORIC's scientific founders are Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering novel targets in cancer that have led to innovative treatments. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed, EcoR1, Fidelity, Foresite and others. ORIC is headquartered in South San Francisco, California.
SOURCE Oric Pharmaceuticals